Sarepta Therapeutics, Inc.

816 articles with Sarepta Therapeutics, Inc.

• AVI BioPharma, Inc.'s NEUGENE Shows Success Against Deadly Ebola Virus; Results Published In Online Journal Public Library Of Science (PLoS) Pathogens

  1/13/2006

• AVI BioPharma, Inc. Reports Favorable Safety And Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus

  1/10/2006

• Increased Defense-Related Funding Of AVI BioPharma Approved; $11 Million Allocated For Development Of Therapeutics For Ebola, Marburg And Dengue Viruses, And For Countermeasures For Anthrax And Ricin Toxins

  1/4/2006

• AVI BioPharma, Inc. Announces $22.6 Million Direct Equity Placement

  11/15/2005

• AVI BioPharma, Inc. Reports Third Quarter Financial Results

  11/4/2005

• Results From AVI BioPharma, Inc.'s Antiviral Program Published In Two Virology Journals

  10/25/2005

• AVI BioPharma, Inc. Provides Update On Influenza Drug Development Program

  10/20/2005

• AVI BioPharma, Inc. Releases Good Neugene Animal Data

  10/14/2005

• AVI BioPharma Included In Initial Defense Funding Allocation

  10/3/2005

• AVI BioPharma, Inc. To Testify Before Congressional Committee On Bioterrorism Research And Development

  6/9/2005

• AVI BioPharma, Inc. (AVII) Announces Positive Results In NEUGENE Antisense Studies With Collaborators Targeting Emerging Viral Diseases

  4/12/2005

• Biotech Versus Bioterror

  2/14/2005

• AVI BioPharma And USAMRIID Announce NEUGENE Antisense Drug Demonstrates Efficacy Against Ebola Virus

  11/1/2004

• AVI BioPharmaTo Testify Before Congressional Committee On Legislative Proposal For BioShield II

  10/6/2004

• AVI BioPharma Announces NEUGENE Antisense Collaboration With USAMRIID On Biodefense Agents

  8/10/2004

• West Nile Drug Makers To End Research Due To Financial And Logistical Concerns

  4/7/2004